VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS

  • Ariel Florențiu
  • Radu Lichiardopol
Keywords: diabetes treatment, DPP-4 inhibitors, vildagliptin

Abstract

Novel therapeutic approaches are continuously being researched in type 2 diabetes. The incretin class of anti-diabetic agents, consisting of glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors, has already found an important place in the current guidelines. Vildagliptin is a potent dipeptidyl peptidase-4 inhibitor, with numerous trials in type 2 diabetes treatment, both in monotherapy and in combination therapy. This review focuses on vildagliptin pharmacological properties, clinical efficacy and safety, and pharmacoeconomic data.

Published
2013-06-15
How to Cite
Florențiu, Ariel, and Radu Lichiardopol. 2013. “VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS”. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 20 (2), 165-76. http://rjdnmd.org/index.php/RJDNMD/article/view/236.
Section
Review Articles